Rami S. Komrokji

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes

David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero et al. · Journal of Clinical Oncology · 2021 · 460 citations · Full text

Medicine, Oncology, Pharmacology +5

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

Ashley A. Basiorka, Kathy L. McGraw, Erika A. Eksioglu et al. · Blood · 2016 · 346 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge et al. · Blood · 2014 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Francesco Passamonti, Toni Giorgino, Barbara Mora et al. · Leukemia · 2017 · 334 citations · Full text

Medicine, Hematology, Molecular Medicine +5